Compare RYTM & BB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYTM | BB |
|---|---|---|
| Founded | 2008 | 1984 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.0B |
| IPO Year | 2017 | 1999 |
| Metric | RYTM | BB |
|---|---|---|
| Price | $105.64 | $9.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 4 |
| Target Price | ★ $131.14 | $4.85 |
| AVG Volume (30 Days) | 872.9K | ★ 31.4M |
| Earning Date | 05-05-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.34 | ★ 169.23 |
| EPS | N/A | ★ 0.09 |
| Revenue | N/A | ★ $549,100,000.00 |
| Revenue This Year | $55.34 | $12.21 |
| Revenue Next Year | $86.06 | $8.95 |
| P/E Ratio | ★ N/A | $101.17 |
| Revenue Growth | N/A | ★ 2.65 |
| 52 Week Low | $74.50 | $3.12 |
| 52 Week High | $122.20 | $13.59 |
| Indicator | RYTM | BB |
|---|---|---|
| Relative Strength Index (RSI) | 53.92 | 40.95 |
| Support Level | $98.30 | $8.21 |
| Resistance Level | $113.51 | $10.93 |
| Average True Range (ATR) | 4.38 | 0.90 |
| MACD | -1.22 | -0.37 |
| Stochastic Oscillator | 21.67 | 4.51 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.